FDA seeks foundation board members
This article was originally published in The Tan Sheet
Executive Summary
Patient and consumer advocacy groups, professional scientific and medical societies, and trade groups are encouraged to submit nominations for candidates to serve on the board of directors for the Reagan-Udall Foundation, which is dedicated to modernizing medical, veterinary, food and cosmetic product development to accelerate innovation and enhance product safety, the agency announces in Oct. 3 Federal Register notice. Nominations for the foundation should be submitted by Oct. 15; the initial board is to be appointed no later than 30 days after the Sept. 27 enactment of the FDA reauthorization bill (1"The Tan Sheet" Oct. 1, 2007, p. 11). The board will include 14 members, five selected through nominations and nine by the National Academy of Sciences...
You may also be interested in...
Reagan-Udall pushback
Rep. Rosa DeLauro, D-Conn., wants FDA to halt efforts to establish the Reagan-Udall Foundation, a non-profit advisory body established by the recently enacted FDA Amendments Act. "The potential for pressure on FDA staff from Reagan-Udall Foundation-endorsed research is enormous," the chair of the House subcommittee overseeing FDA's budget writes in a Nov. 1 letter to Commissioner Andrew von Eschenbach. The foundation, to be funded from donations, patent revenue and FDA's budget, is tasked to work with FDA on its critical path initiative and other product development efforts (1"The Tan Sheet" Oct. 8, 2007, In Brief). By law, four members of the yet-unnamed 14-person foundation board must be from the drug, device, food, cosmetic and biotech industries...
Pre-emption Limits Survive Congress, But Will Face Supreme Court
The FDA reauthorization law signed by President Bush Sept. 27 includes provisions intended to sustain limits on federal pre-emption, but the concept is challenged in several ongoing cases that could reach the Supreme Court in coming sessions
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”